Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 79

1.

Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.

Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, Brell JM, Siu LL.

J Clin Oncol. 2012 Aug 10;30(23):2919-28. doi: 10.1200/JCO.2011.39.7356. Epub 2012 Jul 9.

PMID:
22778315
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.

Barrett D, Brown VI, Grupp SA, Teachey DT.

Paediatr Drugs. 2012 Oct 1;14(5):299-316. doi: 10.2165/11594740-000000000-00000. Review.

PMID:
22845486
[PubMed - indexed for MEDLINE]
3.

Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.

Gallagher EJ, Fierz Y, Vijayakumar A, Haddad N, Yakar S, LeRoith D.

Oncogene. 2012 Jul 5;31(27):3213-22. doi: 10.1038/onc.2011.495. Epub 2011 Oct 31.

PMID:
22037215
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Wu P, Hu YZ.

Curr Med Chem. 2010;17(35):4326-41. Review.

PMID:
20939811
[PubMed - indexed for MEDLINE]
5.

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.

Burris HA 3rd.

Cancer Chemother Pharmacol. 2013 Apr;71(4):829-42. doi: 10.1007/s00280-012-2043-3. Epub 2013 Feb 3. Review.

PMID:
23377372
[PubMed - indexed for MEDLINE]
6.

Targeting the phosphoinositide 3-kinase pathway in cancer.

Liu P, Cheng H, Roberts TM, Zhao JJ.

Nat Rev Drug Discov. 2009 Aug;8(8):627-44. doi: 10.1038/nrd2926. Review.

PMID:
19644473
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.

Maira SM, Furet P, Stauffer F.

Future Med Chem. 2009 Apr;1(1):137-55. doi: 10.4155/fmc.09.5. Review.

PMID:
21426073
[PubMed - indexed for MEDLINE]
8.

Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

Zhou Q, Lui VW, Yeo W.

Future Oncol. 2011 Oct;7(10):1149-67. doi: 10.2217/fon.11.95. Review. Erratum in: Future Oncol. 2012 Jan;8(1):112.

PMID:
21992728
[PubMed - indexed for MEDLINE]
9.

Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.

Ghayad SE, Cohen PA.

Recent Pat Anticancer Drug Discov. 2010 Jan;5(1):29-57. Review.

PMID:
19751211
[PubMed - indexed for MEDLINE]
10.

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA.

Drug Resist Updat. 2008 Feb-Apr;11(1-2):32-50. doi: 10.1016/j.drup.2007.11.003. Epub 2007 Dec 31. Review.

PMID:
18166498
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

[PI3K-AKT-mTOR pathway inhibitors].

Cortot A, Armand JP, Soria JC.

Bull Cancer. 2006 Jan;93(1):19-26. Review. French.

PMID:
16455502
[PubMed - indexed for MEDLINE]
12.

Development of PI3K inhibitors: lessons learned from early clinical trials.

Rodon J, Dienstmann R, Serra V, Tabernero J.

Nat Rev Clin Oncol. 2013 Mar;10(3):143-53. doi: 10.1038/nrclinonc.2013.10. Epub 2013 Feb 12. Review.

PMID:
23400000
[PubMed - indexed for MEDLINE]
13.

Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.

Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, Ronen SM.

Neuro Oncol. 2012 Mar;14(3):315-25. doi: 10.1093/neuonc/nor209. Epub 2011 Dec 12.

PMID:
22156546
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?

Zardavas D, Fumagalli D, Loi S.

Curr Opin Oncol. 2012 Nov;24(6):623-34. doi: 10.1097/CCO.0b013e328358a2b5. Review.

PMID:
22960556
[PubMed - indexed for MEDLINE]
15.

The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.

Slomovitz BM, Coleman RL.

Clin Cancer Res. 2012 Nov 1;18(21):5856-64. doi: 10.1158/1078-0432.CCR-12-0662. Epub 2012 Oct 18. Review.

PMID:
23082003
[PubMed - indexed for MEDLINE]
Free Article
16.

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

Martelli AM, Evangelisti C, Chiarini F, McCubrey JA.

Oncotarget. 2010 Jun;1(2):89-103. Review.

PMID:
20671809
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

PI3K/AKT/mTOR inhibitors in ovarian cancer.

Mazzoletti M, Broggini M.

Curr Med Chem. 2010;17(36):4433-47. Review.

PMID:
21062259
[PubMed - indexed for MEDLINE]
18.

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A, Mangold GL, Patnaik A.

Clin Cancer Res. 2012 Apr 15;18(8):2316-25. doi: 10.1158/1078-0432.CCR-11-2381. Epub 2012 Jan 19.

PMID:
22261800
[PubMed - indexed for MEDLINE]
Free Article
19.

Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.

Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, Ye WC.

Carcinogenesis. 2013 Jun;34(6):1331-42. doi: 10.1093/carcin/bgt060. Epub 2013 Feb 7.

PMID:
23393227
[PubMed - indexed for MEDLINE]
Free Article
20.

Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies.

Schatz JH.

Curr Oncol Rep. 2011 Oct;13(5):398-406. doi: 10.1007/s11912-011-0187-7.

PMID:
21755275
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk